- Home
- ATEN vs ATAI Comparison
ATEN vs ATAI Comparison
Compare ATEN & ATAI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | ATEN | ATAI |
|---|---|---|
| Founded | 2004 | 2018 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | EDP Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.2B | 1.5B |
| IPO Year | 2014 | 2021 |
Fundamental Metrics
Financial Performance| Metric | ATEN | ATAI |
|---|---|---|
| Price | $21.02 | $3.83 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 4 | 7 |
| Target Price | ★ $23.75 | $15.57 |
| AVG Volume (30 Days) | 668.0K | ★ 4.5M |
| Earning Date | 05-04-2026 | 01-01-0001 |
| Dividend Yield | ★ 1.15% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ 0.57 | N/A |
| Revenue | ★ $235,429,000.00 | $308,000.00 |
| Revenue This Year | $12.96 | N/A |
| Revenue Next Year | $10.18 | $285.00 |
| P/E Ratio | $36.77 | ★ N/A |
| Revenue Growth | ★ 2.36 | N/A |
| 52 Week Low | $13.81 | $1.15 |
| 52 Week High | $21.31 | $6.73 |
Technical Indicators
Market Signals| Indicator | ATEN | ATAI |
|---|---|---|
| Relative Strength Index (RSI) | 64.09 | 49.87 |
| Support Level | $17.04 | $3.42 |
| Resistance Level | $21.31 | $4.46 |
| Average True Range (ATR) | 0.66 | 0.27 |
| MACD | 0.05 | 0.02 |
| Stochastic Oscillator | 90.77 | 45.26 |
Price Performance
Historical ComparisonAbout ATEN A10 Networks Inc.
A10 Networks Inc is a provider of security and infrastructure solutions for on-premises, hybrid cloud, and edge-cloud environments of its multinational enterprise, communication, cloud and web service provider customers who strive to provide business-critical applications and networks that are secure, available, and efficient. As cyber-attacks increase in volume and complexity, the company integrates security and artificial intelligence (AI) enabled capabilities in its solutions that enable its customers to continue to adapt to market trends in hybrid cloud, AI-ready data centers and the ever-increasing need for high-performance, high availability and low latency. The company generates the maximum of its revenue from Americas.
About ATAI ATAI Life Sciences N.V.
AtaiBeckley Inc is a clinical-stage biopharmaceutical company on a mission to transform patient outcomes by developing effective, rapid-acting, and convenient mental health treatments. AtaiBeckley's pipeline of novel therapies includes BPL-003 (mebufotenin benzoate nasal spray) for treatment-resistant depression (TRD), VLS-01 (DMT buccal film) for TRD and EMP-01 ((R)-MDMA HCI) for social anxiety disorder, which are in Phase 2 clinical development.